Digital PCR for the Analysis of Copy Number Variation in Lung Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2020 Oct 5

PMID 33014186

Citations 4

Authors

Alexander Brik

Daniel G Weber

Swaantje Casjens

Peter Rozynek

Swetlana Meier

Thomas Behrens

Georgios Stamatis

Kaid Darwiche

Dirk Theegarten

Thomas Bruning

Georg Johnen

Affiliations

Soon will be listed here.

Abstract

Background: (v-myc avian myelocytomatosis viral oncogene homolog) is one of the most frequently amplified genes in lung tumors. For the analysis of gene copy number variations, dPCR (digital PCR) is an appropriate tool. The aim of our study was the assessment of dPCR for the detection of copy number variations (CNV) in lung tissue considering clinicopathological parameters. . status was analyzed with dPCR as well as qPCR (quantitative PCR) using gDNA (genomic DNA) from tumor and adjacent nontumor tissue samples of lung cancer patients. The performance of was estimated based on the AUC (area under curve).

Results: The results of the amplification correlated significantly between dPCR and qPCR ( = 0.81, < 0.0001). The copy number revealed by dPCR showed statistically significant differences between tumor and adjacent nontumor tissues. For discrimination, a sensitivity of 43% and a specificity of 99% were calculated, representing 55 true-positive and one false-positive tests. No statistically significant differences could be observed for age, sex, and smoking status or the clinicopathological parameters (histological subtype, grade, and stage).

Conclusion: The results of the study show that dPCR is an accurate and reliable method for the determination of copy numbers. The application is characterized by high specificity and moderate sensitivity. amplification is a common event in lung cancer patients, and it is indicated that the determination of the status might be useful in clinical diagnostics.

Citing Articles

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.

Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T Leukemia. 2024; 38(8):1712-1721.

PMID: 38914716 PMC: 11286529. DOI: 10.1038/s41375-024-02301-y.

Digital PCR for Single-Cell Analysis.

Fang W, Liu X, Maiga M, Cao W, Mu Y, Yan Q Biosensors (Basel). 2024; 14(2).

PMID: 38391982 PMC: 10886679. DOI: 10.3390/bios14020064.

Assessment of MYC and TERT copy number variations in lung cancer using digital PCR.

Brik A, Wichert K, Weber D, Szafranski K, Rozynek P, Meier S BMC Res Notes. 2023; 16(1):279.

PMID: 37858127 PMC: 10585721. DOI: 10.1186/s13104-023-06566-x.

Evaluate the Prognosis of Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study.

Cao J, Gu J, Liang Y, Wang B Technol Cancer Res Treat. 2022; 21:15330338221138213.

PMID: 36524293 PMC: 9761218. DOI: 10.1177/15330338221138213.

References

Chen H, Liu H, Qing G . Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018; 3:5. PMC: 5837124. DOI: 10.1038/s41392-018-0008-7. View

Iwakawa R, Kohno T, Kato M, Shiraishi K, Tsuta K, Noguchi M . MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res. 2010; 17(6):1481-9. DOI: 10.1158/1078-0432.CCR-10-2484. View

Kim H, Mitsudomi T, Soo R, Cho B . Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer. 2013; 80(3):249-55. DOI: 10.1016/j.lungcan.2013.02.015. View

Sanders R, Huggett J, Bushell C, Cowen S, Scott D, Foy C . Evaluation of digital PCR for absolute DNA quantification. Anal Chem. 2011; 83(17):6474-84. DOI: 10.1021/ac103230c. View

Qin J, Jones R, Ramakrishnan R . Studying copy number variations using a nanofluidic platform. Nucleic Acids Res. 2008; 36(18):e116. PMC: 2566873. DOI: 10.1093/nar/gkn518. View

Flacco A, Ludovini V, Bianconi F, Ragusa M, Bellezza G, Tofanetti F . MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer. Am J Clin Oncol. 2015; 38(2):152-8. PMC: 4607281. DOI: 10.1097/COC.0000000000000012. View

Pfarr N, Penzel R, Klauschen F, Heim D, Brandt R, Kazdal D . Copy number changes of clinically actionable genes in melanoma, non-small cell lung cancer and colorectal cancer-A survey across 822 routine diagnostic cases. Genes Chromosomes Cancer. 2016; 55(11):821-33. DOI: 10.1002/gcc.22378. View

Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M . Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg. 2001; 7(4):197-203. View

Bowcock A . Invited review DNA copy number changes as diagnostic tools for lung cancer. Thorax. 2013; 69(5):495-6. DOI: 10.1136/thoraxjnl-2013-204681. View

10.

Whale A, Huggett J, Cowen S, Speirs V, Shaw J, Ellison S . Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res. 2012; 40(11):e82. PMC: 3367212. DOI: 10.1093/nar/gks203. View

11.

Hwang D, Sun H, Rodig S, Hornick J, Sholl L . Myc protein expression correlates with MYC amplification in small-cell lung carcinoma. Histopathology. 2014; 67(1):81-9. DOI: 10.1111/his.12622. View

12.

Soucek L, Evan G . The ups and downs of Myc biology. Curr Opin Genet Dev. 2009; 20(1):91-5. PMC: 2822095. DOI: 10.1016/j.gde.2009.11.001. View

13.

Yong R, Mustaffa S, Wasan P, Sheng L, Marshall C, Scherer S . Complex Copy Number Variation of AMY1 does not Associate with Obesity in two East Asian Cohorts. Hum Mutat. 2016; 37(7):669-78. DOI: 10.1002/humu.22996. View

14.

Schaub F, Dhankani V, Berger A, Trivedi M, Richardson A, Shaw R . Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Syst. 2018; 6(3):282-300.e2. PMC: 5892207. DOI: 10.1016/j.cels.2018.03.003. View

15.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

16.

Albertson D . Gene amplification in cancer. Trends Genet. 2006; 22(8):447-55. DOI: 10.1016/j.tig.2006.06.007. View

17.

Lockwood W, Chari R, Coe B, Girard L, MacAulay C, Lam S . DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. Oncogene. 2008; 27(33):4615-24. PMC: 2849646. DOI: 10.1038/onc.2008.98. View

18.

Kline M, Romsos E, Duewer D . Evaluating Digital PCR for the Quantification of Human Genomic DNA: Accessible Amplifiable Targets. Anal Chem. 2016; 88(4):2132-9. PMC: 5108050. DOI: 10.1021/acs.analchem.5b03692. View

19.

Jabs V, Edlund K, Konig H, Grinberg M, Madjar K, Rahnenfuhrer J . Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer. PLoS One. 2017; 12(11):e0187246. PMC: 5675410. DOI: 10.1371/journal.pone.0187246. View

20.

Johnen G, Krismann M, Jaworska M, Muller K . [CGH findings in neuroendocrine tumours of the lung]. Pathologe. 2003; 24(4):303-7. DOI: 10.1007/s00292-003-0623-z. View